Supernus Pharmaceuticals, Inc.SUPNNASDAQ
LOADING
|||
EBITDA Over Time
Trending higher, above historical average, strong compound growth.
Left:
||||
Earnings before interest, taxes, depreciation, and amortization
Latest
$178.28M
↑ 39% above average
Average (9y)
$127.94M
Historical baseline
Range
High:$210.54M
Low:$21.77M
CAGR
+26.3%
Consistent expansion
| Period | Value | Change |
|---|---|---|
| 2024 | $178.28M | +98.0% |
| 2023 | $90.04M | -41.3% |
| 2022 | $153.36M | +18.7% |
| 2021 | $129.19M | -38.6% |
| 2020 | $210.54M | +16.7% |
| 2019 | $180.42M | +19.1% |
| 2018 | $151.51M | +40.7% |
| 2017 | $107.67M | +90.2% |
| 2016 | $56.62M | +160.1% |
| 2015 | $21.77M | - |